It’s only fair to share… PF 04937319, NERIGLIATIN N,N-dimethyl-5-(2-methyl-6-((5-methylpyrazin-2-yl)-carbamoyl)benzofuran-4-yloxy)pyrimidine-2-carboxamide MW 432.43, MF C22 H20 N6 O4 CAS 1245603-92-2 2-Pyrimidinecarboxamide, N,N-dimethyl-5-[[2-methyl-6-[[(5-methyl-2-pyrazinyl)amino]carbonyl]-4-benzofuranyl]oxy]- N,N-Dimethyl-5-(2-methyl-6-((5-methylpyrazin-2-yl)carbamoyl)-benzofuran-4- yloxy)pyrimidine-2-carboxamide Pfizer Inc. clinical candidate currently in Phase 2 development. SCHEME REF MedChemComm (2011), 2(9), 828-839 81% WO2010103437 CLINICAL TRIALS A trial to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of PF-04937319 …